UgenTec develops intelligent PCR software and is now part of Velsera, following its acquisition by Summa Equity. When I came on board in 2015, UgenTec was working with seed funding and preparing for Series A fundraising.
To attract investors, the company needed proof of concept and early market traction. I identified, approached and closed deals with several early adopters of its intelligent PCR software.
These early adopter deals helped convince investors with and without life science experience to invest. UgenTec went on to become a biotech software success story.
Katrien joined UgenTec from its early beginnings. Her experience in international sales and marketing, her network and diagnostics/biotech market knowledge are key to our company. She offers valuable market feedback for product development and business planning, which contributes greatly to the growth of UgenTec.
It is also a pleasure to work with Katrien. Her flexible and no-nonsense approach, plus her combination of academic and business experience, is just what a young company such as UgenTec needs.
